Owen Hughes
Net worth: 7 M $ as of 2026-05-30
Net worth: 7 M $ as of 2026-05-30
Owen Patrick Hughes founded Triathlon Fund Management LLC in 2003, where he worked as Partner from 2003 to 2006, Cullinan Therapeutics, Inc. in 2016, where he worked as President, Chief Executive Officer & Director from 2017 to 2021, and Cullinan Oncology LLC in 2016, where he worked as President, Chief Executive Officer & Director from 2017 to 2021.
Mr. Hughes also currently works at XOMA Royalty Corp., as Chief Executive Officer & Director from 2024, Kinnate Biopharma, Inc., as Chief Executive Officer, CFO & Secretary, Mural Oncology Plc, as Chief Executive Officer, Director & Secretary from 2025, Generation Bio Co., as President, Secretary, Treasurer & Director from 2026, AnaptysBio, Inc., as Director from 2026, C4 Therapeutics, Inc., as Independent Director from 2023, Olivo Laboratories LLC, as Director, Wavebreak Therapeutics Ltd., as Director from 2018, LAVA Therapeutics NV, as Executive Director from 2025, Turnstone Biologics Corp., as President, Secretary & Treasurer from 2025, and XRA 5 Corp., as President, Secretary & Treasurer.
Mr. Hughes also formerly worked at Sail Bio, Inc., as Chief Executive Officer, Radius Health, Inc., as Chairman from 2020 to 2022, Ikena Oncology, Inc., as Chairman, Bain Capital Public Equity LP, as Director in 2011, Brookside Capital Investors LP, as Director, Translate Bio, Inc., as Lead Independent Director in 2021, Malin Corp.
Plc, as Independent Non-Executive Director from 2015 to 2018, Bain Capital LP, as Director, Brookside Capital, Inc., as Director from 2008 to 2013, FS Development Corp.
II, as Independent Director, Ziff Brothers Investments LLC, as Investment Associate from 2001 to 2003, PaineWebber, Inc., as Financial Analyst, Merrill Lynch Global Private Equity, Inc., as Assistant Vice President from 1998 to 2001, Intarcia Therapeutics, Inc., as Chief Business Officer from 2013 to 2017, and FIAM LLC, as Portfolio Manager from 2006 to 2008.
Mr. Hughes received his undergraduate degree from Dartmouth College.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-04 | 109,588 ( 0.87% ) | 5 M $ | 2026-05-30 | |
| 2026-06-04 | 102,000 ( 5.79% ) | 3 M $ | 2026-05-30 | |
| 2026-06-23 | 0 ( -.--% ) | - $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| XOMA ROYALTY CORPORATION | Chief Executive Officer | 2022-12-31 |
| C4 THERAPEUTICS, INC. | Director/Board Member | 2023-11-19 |
| TURNSTONE BIOLOGICS CORP. | President | 2025-08-10 |
| LAVA THERAPEUTICS N.V. | Director/Board Member | 2025-11-06 |
| GENERATION BIO CO. | President | 2026-02-05 |
| KINNATE BIOPHARMA INC. | Chief Executive Officer | - |
| ANAPTYSBIO, INC. | Director/Board Member | 2026-05-10 |
Olivo Laboratories LLC
Olivo Laboratories LLC Medical/Nursing ServicesHealth Services Provides solutions to skin-related medical problems through proprietary biomaterials technologies | Director/Board Member | - |
Wavebreak Therapeutics Ltd.
Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops small molecule therapeutics for multiple protein misfolding diseases | Director/Board Member | 2018-11-28 |
| Companies | Position | End |
|---|---|---|
| ░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 28 |
|---|---|
XOMA Royalty Corp.
XOMA Royalty Corp. Pharmaceuticals: MajorHealth Technology Discovers and develops antibody therapeutics | Health Technology |
Bain Capital Public Equity LP
Bain Capital Public Equity LP Investment ManagersFinance Bain Capital Public Equity employs long/short equity strategies that combine rigorous bottom-up, fundamental research with analytical portfolio construction to identify and capitalize on opportunities across the global equity markets. The firm seeks to achieve isolate alpha and generate attractive returns over a full market and industry cycle with low correlation to the equity markets. Their investment advisory activity focuses on advising the Public Equity Funds on investments in securities of publicly traded companies that offer opportunities to realize substantial long-term appreciation. Bain Capital Public Equity typically makes investments in securities at prices it believes to be below their intrinsic value based on a company’s normalized cash flow, growth potential and/or asset value. | Finance |
Brookside Capital Investors LP | |
Radius Health, Inc.
Radius Health, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and commercializes bone health and related therapeutics | Health Technology |
Triathlon Fund Management LLC
Triathlon Fund Management LLC Investment ManagersFinance Triathlon Fund Management invests in stocks in North America and Europe focusing on the biotechnology sector. They are primarily small-cap investors that maintain a high turnover rate. | Finance |
AnaptysBio, Inc.
AnaptysBio, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company | Health Technology |
Translate Bio, Inc.
Translate Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage mRNA therapeutics company that develops transformative medicines to treat diseases caused by protein | Health Technology |
Malin Corp. Plc
Malin Corp. Plc BiotechnologyHealth Technology Provides life science services | Health Technology |
Dartmouth College
Dartmouth College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bain Capital LP
Bain Capital LP Financial ConglomeratesFinance Provides investment services | Finance |
Brookside Capital, Inc.
Brookside Capital, Inc. Investment ManagersFinance Brookside Capital designs, implements, and manages customized portfolios of liquid assets for their clients. In selecting assets, the firm's decision-making process begins with consideration of long-term social, economic, and political themes. Portfolio investments may include domestic and foreign equities, fixed-income securities, mutual funds, exchange-traded funds, and limited partnerships, as well as cash equivalents. | Finance |
Ziff Brothers Investments LLC
Ziff Brothers Investments LLC Investment ManagersFinance Ziff Brothers Investments is an active investor, and manages portfolios invested in both publicly listed and private securities across asset classes, borders and a broad range of sectors, including energy, and high-technology. | Finance |
PaineWebber, Inc.
PaineWebber, Inc. Investment Banks/BrokersFinance Provides stock brokerage and asset management services | Finance |
Merrill Lynch Global Private Equity, Inc.
Merrill Lynch Global Private Equity, Inc. Investment ManagersFinance MLGP's objective is to generate long-term capital gains, with a primary focus on control-oriented investments in equity, equity-related and similar securities with equity-like returns. Investments typically range in size from $250 million to $750 million, with the flexibility to commit to larger or smaller investments. MLGP makes investments globally, with a primary emphasis on the world's largest economies, including the US, Europe, Japan, China, India, Latin America and Australia, taking a multi-sector approach to identifying attractive investment opportunities. They target investments in high quality, established companies that are recognized brands with industry or regional leadership, defensible market positions, strong cash flow characteristics and seasoned management. They combine comprehensive regional and industry-based in-depth analyses with global approval and management processes. Their approach combines an intensive, bottom-up evaluation process including gaining a detailed understanding of a potential portfolio company's value drivers, management capabilities, cost structure, cash flow characteristics, market position and competitive advantages with a top-down analysis of the attractiveness, growth potential and underlying economics of the industry, competitive environment and exit alternatives. When making an investment, MLGPE takes a control-oriented approach and seeks to structure transactions to ensure the ability to influence critical decisions for a portfolio company, particularly as it relates to specific value-added initiatives. A key element of their transaction negotiation with partners and management centers on contractual rights and board representation that facilitate input into key decisions such as management changes, expansion plans, acquisitions, budgets, debt and equity financings and new initiatives. MLGP implements value creation initiatives such as organic growth alternatives, acquisitions and other strategic initiatives, business rationalization and operational improvements and capital structure improvements in partnership with portfolio company management. They are actively involved in significant portfolio company decisions, including those relating to potential acquisitions, expansion plans, debt and equity financings, changes in senior management and new business initiatives. | Finance |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops innovative therapies utilizing the Medici drug delivery system | Health Technology |
FIAM LLC
FIAM LLC Investment ManagersFinance FIAM utilizes a variety of methods of security analysis to select investments, including fundamental, quantitative, technical and macro-economic analysis in managing client accounts. The firm's global research resources include seasoned, sector-focused fundamental analysts covering industry sectors across the US and global markets as well as quantitative and technical portfolio managers and analysts. | Finance |
C4 Therapeutics, Inc.
C4 Therapeutics, Inc. BiotechnologyHealth Technology Develops targeted protein degradation therapeutics for the treatment of cancer | Health Technology |
Olivo Laboratories LLC
Olivo Laboratories LLC Medical/Nursing ServicesHealth Services Provides solutions to skin-related medical problems through proprietary biomaterials technologies | Health Services |
Wavebreak Therapeutics Ltd.
Wavebreak Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops small molecule therapeutics for multiple protein misfolding diseases | Health Technology |
Ikena Oncology, Inc.
Ikena Oncology, Inc. BiotechnologyHealth Technology Develops metabolic enzymes based immunotherapy for oncology applications | Health Technology |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Provides investment services for cancer treatments | Finance |
Generation Bio Co.
Generation Bio Co. Pharmaceuticals: MajorHealth Technology Develops and commercializes genetic medicines | Health Technology |
LAVA Therapeutics NV
LAVA Therapeutics NV Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops antibodies for the treatment of cancer | Health Technology |
Turnstone Biologics Corp.
Turnstone Biologics Corp. BiotechnologyHealth Technology Develops and sells medicines to treat and cure solid tumors | Health Technology |
Kinnate Biopharma, Inc.
Kinnate Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage precision oncology company | Health Technology |
Cullinan Oncology, Inc.
Cullinan Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
FS Development Corp. II
FS Development Corp. II Financial ConglomeratesFinance Operates as a blank check company | Finance |
Sail Bio, Inc. | Electronic Technology |
Select your edition
All financial news and data tailored to specific country editions